Introduction
In a series of now classical papers published mainly in the 1970s, Wagenvoort and coworkers described thrombosis of small pulmonary arteries as one of the typical histopathological features of idiopathic pulmonary arterial hypertension (IPAH), a disease called primary pulmonary hypertension (PPH) at that time. [1] [2] [3] This observation, together with studies demonstrating hypercoagulability in patients with severe pulmonary hypertension (PH), [4] [5] [6] led to the hypothesis that in-situ thrombosis of altered pulmonary vessels may contribute to disease progression and was associated with a better survival. 7 A later study by Rich et al. also showed improved survival in patients receiving anticoagulants. 8 This study, albeit prospective, was not randomized, had a relatively small sample size (n=64) and the use of anticoagulation was based on the presence of scintigraphic perfusion abnormalities, thereby potentially generating some bias. A systematic review of the literature found 7 studies, 5 of which suggested benefit and 2 of which were negative. 9 So far, no prospective, randomized clinical trial has been conducted to assess the use of anticoagulants in patients with PAH. Taken together, there is a clear pathophysiological rationale to use anticoagulation in patients with IPAH, which is supported by preliminary clinical data, but scientific evidence remains limited.
The situation is even less clear for patients with other forms of PAH, for which there is almost no published evidence for or against the use of anticoagulation. Some of these patients are at increased risk for bleeding complications, in particular those with connective tissue disease, confirmed the presence of thrombotic pulmonary vascular lesions in patients wi ith th h P P PPH PH H a a and nd nd demonstrated, based on a retrospective analysis of 120 patients, that the use of anticoagulants wa was s s as as ss so soci ci ciat at ate e ed w w wit it ith h a better survival. 7 A later stu tu udy dy y by Rich et al l. . also o s s sh ho howed improved surviva congenital heart disease and liver disease. [10] [11] [12] All of these factors have been taken into consideration by the current PH guidelines, which acknowledge the low level of evidence for all PAH subpopulations but recommend anticoagulation as supportive therapy for patients with IPAH while providing a more ambiguous recommendation for patients with other forms of PAH. [13] [14] [15] Based on the lack of sound evidence, there is an ongoing controversy surrounding the use of anticoagulants in patients with PAH. The above-mentioned data were generated at a time when almost no targeted therapies were available for PAH. More recently, efficacious treatments have been developed for PAH, which have led to improvements in hemodynamics, exercise capacity and survival. [16] [17] [18] At the same time, the demographics of these patients have been changing, at least in the western world, with PAH now being frequently diagnosed in older patients with abundant co-morbidities. [19] [20] [21] [22] It is unclear whether these patients still benefit from anticoagulation, especially as bleeding rates of 5.4 per 100 years in patients with IPAH and of 19
per 100 years in patients with connective tissue disease and PAH have been reported. 23 In order to obtain further data on anticoagulation in patients with PAH, we analyzed the COMPERA database. COMPERA is an ongoing, investigator-initiated, non-interventional, prospective European-based registry that enrolls patients with all forms of PH. 21 We hypothesized that a large, prospective registry might be a valuable tool to further assess the effects of anticoagulation on the contemporary long-term outcome of patients with various forms of PAH.
Methods

Setting and participants
COMPERA is a PH registry that was launched in July 2007 and continues to enroll patients capacity and survival. [16] [17] [18] At the same time, the demographics of these patients h ha have ve v b b bee ee een n n changing, at least in the western world, with PAH now being fr r equently diagnosed in older pa ati ti ien en ents ts ts w w wit it ith h h abun un unda da d nt co-morbidities. [19] [20] [21] [22] It is u u unc nc n l lear whether t the he h se pa pa pat ti tients still benefit from an nti i ico c agulatio on, n, es s spec ec cia all ll lly y as as as b b ble leed ed edin in i g g g r ra ates s o of 5.4 4 4 p per r 1 10 00 0 ye e ear ars s s i in n p pat at tie ent nts s s w w wit ith h IP IP IPAH AH AH a a and n nd o of f f 19 pe per r r 10 10 00 0 0 ye ye year ar ars s s in in pa at atie ien n nts s s wi w th th h c con on onne ne nect cti iv ive e e ti ti tis s ssue ue ue d di i ise e eas se se a a and nd nd P P PAH AH AH h h hav av ave e be e een en n r rep ep epor or rte te ted d. 23 3 3 In ord der er e t to o o ob ob obta ta ain in n f f fur ur u th th ther er r d d dat at ta a a on on on a a ant nt ntic ic icoa oa oagu gu gula la lati ti t on n n i in n n pa pa pati ti tien en ents s s w w wit it ith h h PA PA PAH, H, H, w w we e e an an anal a yzed the (Clinical trials registration: www.clinicaltrials.gov NCT01347216). 21 The patients on a consecutive basis. Data are collected at the time of diagnosis (baseline), i.e. the time of the first right heart catheterization, and at least in 6-monthly intervals or whenever the patient has a predefined clinical event (death, transplantation, PAH-related hospitalization, deterioration in functional class, any unscheduled change in PAH therapy, or other serious adverse events).
Out-of-range data or missing values are automatically queried during data entry. As of April 2013, source data have been randomly monitored onsite in 22 of 41 (54%) participating centers.
The cut-off date for the present analysis was April 13, 2013 ; at that time 4,069 patients had been enrolled into the database.
Inclusion criteria for the present analysis were a diagnosis of PAH, age 18 years, and availability of data from right heart catheterization at diagnosis showing a mean pulmonary artery pressure (PAPm) 25 mmHg and a mean pulmonary arterial wedge pressure (PAWP) 15 mmHg. Patients who were diagnosed with PAH prior to May 2007 were excluded in order to ensure that the present analysis contains only newly diagnosed (incident) patients. Vitamin K antagonists, heparins and novel oral anticoagulation, but not platelet inhibitors, were considered patients on a consecutive basis. Data are collected at the time of diagnosis (basel eli in ine) e) e , i. i. i.e. e. t t the he he t ti ime of the first right heart catheterization, and at least in 6-monthly intervals or whenever the patient ha as s a a a pr pr pred ed edef ef efin in ined d c c cl li lini n cal event (death, transplant nt ta at atio on, PAH-relat ted ed e hos os sp pi pitalization, deterioration n n f f fun u ctional cl clas as ss, , a an ny y u u uns ns nsch ch ched e edul ul led ed ed cha ha ange e in n n PA A AH H H th h her er rap ap py, y, o or r ot the her r s s ser r riou ou us s ad adve ve vers rs se e e ev eve en ents ts s). .
Ou Ou ut-t-t of of of-r -ran ange ge ge d dat at ta or or m m mis is ssi sing g g v val al alu u ues es es a ar re re a a aut ut utom om omat at a ic ic ca al lly ly yue ue ueri r ried d d d du ur urin in ing g g d da dat ta ta e e ent nt n ry ry ry. As As As of f f A Ap Apri ril l l 2013, source e d d dat at a a a ha ha have ve e b b bee e en n n ra r r nd nd ndom om omly ly m m mon on onit it i or or ored ed ed on on onsi site e e i i in n n 22 22 2 o o of f f 41 1 1 ( (54 54 54%) %) %) pa pa p rt rt rtic ic icip ip ipat at atin in i g centers.
anticoagulants for the present analysis. The database captured these compounds as well as startstop dates. We defined two groups of patients according to the use of anticoagulants: All patients who received therapeutic anticoagulation at any time during the registry were grouped into the "anticoagulation group" whereas patients who never received therapeutic anticoagulation were grouped into the "no anticoagulation group".
Statistical analysis
Categorical data were displayed as number of patients (n) and respective relative frequency. Kaplan-Mei ier er er e e est st s im im imat at ates es es a and nd nd L L Log og og-R -R -an an a k-k-k-te te test st stin in ing. g. g. F F For or r s s su u urv v viv iv ival al al a a ana na naly ly l si si is, s, s, a a all ll l p p pat at atie ient nt nts s s wi wi with th th more than n n multiple testing.
Results
Entire PAH cohort
The whole cohort of patients with incident PAH eligible for analysis consisted of 1,283 patients ( Figure 1 , Table 1 ). Of these, n=738 (58%) received anticoagulants at any time during followup: predominantly (93%) vitamin K antagonists, followed by heparins (6%) and novel oral anticoagulants (1%). The use of anticoagulants remained constant over the years. In the anticoagulation group, 55.7% of the patients received anticoagulants for the entire observation period; 23.3%, 5.8%, 4.3% and 10.8% of the patients received anticoagulants for >75%, 51-75%, 25-50% and <25% of the observation period, respectively. The target international normalized ratio (INR) for vitamin K antagonists was 2-3 in all but one center.
During the 3-year follow-up period, there were 121 deaths (16.4%) in the anticoagulation group and 98 deaths (18.0%) in the no anticoagulation group. Sudden death was reported with similar frequency in both groups (5.0% and 7.1% of all deaths, respectively). The proportion of patients lost to follow-up was 2.2% and 2.4% respectively. The estimated survival probabilities after 1, 2 and 3 years in the anticoagulation group were 92.6%, 84.0% and 74.2%, which were similar to the respective survival rates of the no anticoagulation group (90.8%, 82.2% and 69.6%; p=0.14; Figure 2 ).
IPAH cohort
There were 800 patients in the IPAH cohort, of which 528 (66%) received anticoagulants. The patients in the anticoagulation and no anticoagulation group were comparable in terms of age, gender and functional class at diagnosis but the patients in the anticoagulation group had more period; 23.3%, 5.8%, 4.3% and 10.8% of the patients received anticoagulants fo or r r >7 >7 75% 5% %, , , 51 51 51-7 -7 -75 5%
25-50% and <25% of the observation period, respectively. The target international normalized a ati tio o o (I (I (INR NR NR) ) ) fo fo for vi vi ita ta tami m n K antagonists was 2-3 in n n a all l l but one cente er. r r During g t th he h 3-y -y yea ea ar r fo fo foll ll llo ow ow-u -u up p p pe pe eri io od, th th here w were e e 1 1 121 21 d dea eath th hs (1 (16. 6 6 4% 4% 4%) ) in in in t the he a a ant nt ntic ic i oa oa ag gu gula la l t ti ion gr grou ou oup p p an an a d d 98 98 98 d dea ea ath h hs s ( (1 (18 8. .0% 0%) ) ) in in n t t the he he n no o an an nti ti tico c coag ag agu ul la lat ti ion on n g g gro ro rou up up. . Su Su Sudd dd den en e d d de ea ath th h w w was as a r r rep ep epor rt t ted d d wi wi ith h h imilar freq que ue enc nc ncy y y in in in b bot ot oth h gr gr grou ou oups ps ps ( ( (5. 5. .0% 0% 0% a and nd nd 7 7 7.1 .1 .1% % % of of of a all l d d dea ea eath th ths, s, s, r r res e e pe pe pect ct ctiv iv ivel el ely) y) y . . Th Th The e e pr pr prop o o ortion of severely impaired hemodynamics at the time of diagnosis. Initial PAH medications were comparable in both groups but combination regimens were used more frequently during followup in the anticoagulation group (online supplement, Table 1 ).
During the 3-year follow-up period, there were 75 deaths (14.2%) in the anticoagulation group versus 57 deaths (21.0%) in the no anticoagulation group. The proportions of patients lost to follow-up were 2.1% and 1.8%, respectively. Estimated survival probabilities by KaplanMeier at 1, 2 and 3 years in the anticoagulation group were 94.9%, 86.8% and 76.9%, which was significantly better than the respective survival rates in the no anticoagulation group (90.9%, 80.9% and 66.3%; p=0.006; Figure 3 ). The database contained 34 patients with heritable (n=15) or drug-associated PAH (n=19), who were included in the non-IPAH group (see below). A secondary analysis showed no differences in the survival effect of anticoagulation when these patients were added to the IPAH group (p=0.005 for a survival benefit of the anticoagulation group; data not shown).
Since the anticoagulation and no anticoagulation groups were not entirely comparable in terms of disease severity at baseline, we performed a matched-pair analysis as described above based on gender, age, functional class, and PVR. Using these criteria, 168 randomly matched pairs of patients could be selected for analysis. These patients compared well for the selected criteria as well as for 6MWD and hemodynamics at baseline, but there were significant differences in PAH therapies at baseline and combination therapies during follow-up (online supplement, Table 2 ).
Among these patients, there were 25 deaths (14.9%) in the anticoagulation group and 43 deaths (25.6%) in the no anticoagulation group. The proportion of patients lost to follow-up was 1.8% and 0.6% in the respective groups. The survival difference between both groups remained or drug-associated PAH (n=19), who were included in the non-IPAH group (see e be b belo lo l w) w) w). . A A A econdary analysis showed no differences in the survival effect of anticoagulation when these pa ati ti ien en ents ts ts w w wer er e e e ad dde de ded d to the IPAH group (p=0.005 5 5 f fo or a survival ben en enefit it t o o of f f the anticoagulation f f g grou u up; p data no ot t s sh s o ow own) n n .
Si Sinc nc ce e e th the e an an nti tic co coag ag agul u at at atio ion n n an an and d d n no no a a ant nt ntic icoa oa oagu gu gul la atio o on n n gr gr grou ou ups ps p w w wer er ere e e n n not t t en en nti ti t re re rely ly y c co om omp pa para ra r bl bl le in in erms of disea ea ase se se s sev ev ever er erit it i y y y at at t b b bas a a el el elin in ine, e, e, w w we e e pe pe perf rf rfor or o me me med d d a a a ma ma atc tc tche he hed-d-d pa pa pair r a a ana na naly ly lysi si sis s s as as s d d des es escr cr c ib ib i ed above statistically significant favoring patients in the anticoagulation group (survival rates at 1, 2 and 3 years of 93.9%, 88.2% and 73.6% in the anticoagulation group versus 89.9%, 77.5% and 61.6%
in the no anticoagulation group; p=0.017; Figure 4 ).
In a single predictor Cox regression analysis of baseline variables potentially predicting outcome among IPAH patients (whole group), factors associated with a better outcome were female gender, younger age, NYHA functional classes other than IV, a higher 6 min walking distance and mixed venous oxygen saturation at baseline, and the use of anticoagulants, but not the use of combination therapy. In the multivariable approach, only age, gender, functional class, and the use of anticoagulants remained independent outcome predictors ( Table 2 ).
Other forms of PAH
There were 483 patients with other forms of PAH, the majority of them suffering from PAH associated with connective tissue disease followed by PAH associated with congenital heart disease and portopulmonary hypertension. Of these, 210 patients (43%) were receiving therapeutic anticoagulation. The patients receiving anticoagulation and those not receiving anticoagulation differed in various baseline variables including age, type of PAH, functional class, 6MWD, right atrial pressure and SvO 2 , with all of these variables indicating more severe disease and/or a higher risk of death in patients receiving anticoagulants (online supplement, Table 3 ).
There were 46 deaths (21.9%) in the anticoagulation group and 41 deaths (15.0%) in the no anticoagulation group. The respective numbers of patients lost to follow-up were 2.4% and 2.9%. Kaplan-Meier estimated survival rates at 1, 2 and 3 years were 86.7%, 76.6% and 67.2%
in the anticoagulation group and 90.5%, 83.8% and 73.6% in the no anticoagulation group, a difference that was not statistically significant (p=0.156; Figure 5 ). The results remained
There were 483 patients with other forms of PAH, the majority of them suffering from PAH as sso so oci ci ciat at ated ed ed w w wi it ith co co con nn nnective tissue disease followe we wed d b by PAH assoc cia ia i ted d w wi with congenital heart d di dise e eas a e and po ort rtop op opul lm m mona na nar ry ry h h hy yp yper er rte te ens ns sio o on. O O Of f f thes se e, 210 10 10 p pa a ati ie ent nts s ( (4 43% 3% %) we wer re re r rec ecei ei e vi vi v ng ng g h her er erap ap apeu eu e ti tic c c an a anti tic coa ag agul ul lat atio ion n. Th Th The e e pa pa pati tie en nts ts ts r r rec e ece e eiv iv ivin in ng g an an nti tico co coa ag agul ul ulat atio io i n n n an an and d t th thos os se e no no n t t t re re ece ei iv ivi in ing g anticoagulatio io on n n di di iff ff ffer er e ed ed ed in n n va va vari r ou ou ous s b b bas asel el elin in ne e e va va vari ri r ab ab able le les s s in n ncl cl clud ud udin in ing g g ag ag a e, e, e, t t typ yp ype e e of of of P PAH AH AH, , , fu fu func n n tional unchanged when the HPAH and DPAH patients were removed from this group (p=0.09; data not shown).
In order to further assess the effects of anticoagulation on the outcome of patients with APAH, we selected the subgroup of patients suffering from the scleroderma-spectrum of disease associated with PAH (the sample sizes were too small for analyses of other subpopulations). This group consisted of 208 patients, of whom 104 (50%) were receiving anticoagulants. These patients were comparable in terms of disease severity at baseline, and the use of PAH medications was well matched (online supplement, Figure 6 ). In this group of patients, the use of anticoagulants was associated with a nonsignificant trend toward a worse survival in the single predictor analysis (HR 1.82; 95% CI 0.94 to 3.54; p=0.08).
Serious adverse events or deaths related to bleeding complications
The COMPERA database was not designed to systematically capture all bleeding events but it recorded all serious adverse events, deaths and causes of death (when known). Among the 219 deaths recorded in the present analysis, right heart failure was the leading cause (n=122; 56%).
Bleeding complications (intracerebral bleeding, gastrointestinal bleeding and hemoptysis, one each in the anticoagulation group, and one additional gastrointestinal bleeding event in the no anticoagulation group) were attributed as cause of death in 4 cases (2%). In addition, there were 3 non-fatal but serious bleeding events resulting in hospital admission; all occurred in the patients lost to follow-up were in both groups 2.9%. Kaplan-Meier estimated surv rv viv iv val al r r rat at ates es es a a at t 1, , 2 and 3 years were 82.9%, 70.7% and 62.7% in the anticoagulation group and 86.9%, 80.1% and 73 3.7 .7 7% % % i in in t t the he he n no an an anti ticoagulation group, a differe enc nc n e e that was not s s sta t tist st tic ic ica ally significant (p=0.28; 
Discussion
The present data demonstrate a survival advantage for patients with IPAH treated with anticoagulants, suggesting that these patients continue to benefit from therapeutic anticoagulation in the modern management era. The situation remains inconclusive for patients with other forms of PAH for whom no therapeutic effect of anticoagulation was detectable.
In the present series, anticoagulants were used in 66% of the patients with IPAH, a figure o o u u use s anticoa agu gula l l n nt nts s in i t t thi hi his s s pa pa pati tien en nt t po popu pu ulati i ion n n. T Th he e e av v vai ai ila lab b bil li ity ty of f f a a re re ela at tive ve ely ly ly l lar ar rge ge ge c co oh o o or ort t of of of pa pati ti tien en nts ts t n not ot ot r r rec ece ei ivi vi ing ng g an nt ntic icoa a agu gu gula la lati ti tio on on d d did id d e e en na nabl bl ble e us us us to o o as as sse se ses ss p p pot ot ten n nti ti tial al ef ff ffec ec cts ts t o o of f an an ant ti tico o oag g gul ula a atio o on n on survival. O O Our ur ur d d dat at ata a in in indi d ca ca cate te te tha ha hat t t ph ph phys ys sic ic icia ia ians ns ns t ten en end d d to to o p pre re resc sc scri ri ribe be be a a ant n n ic ic coa oa oagu gu gula la lant nt n s s mo mo more re re f f fre r quently in n n usually designed as short-term trials focusing on improvements in exercise capacity. [25] [26] [27] [28] More recently, however, PAH trials have become long-term studies with morbidity and mortality events as primary outcomes. In the future, such trials should consider the impact of anticoagulation, either by ensuring that all IPAH patients enrolled into such trials do receive anticoagulants, or by stratifying patients according to their use.
The results obtained in patients with other forms of PAH are much more difficult to interpret. It was intriguing to see that 43% of the patients in this group received anticoagulants despite the absence of supportive evidence, the higher risk of bleeding complications and the lack of strong recommendations to use anticoagulants in these patients in current guidelines. [12] [13] [14] [15] This group was heterogeneous and it is almost impossible to compare survival rates of patients with connective tissue disease, congenital heart disease and other forms of PAH. Despite comprising almost 500 patients, this group was still too small for analyzing all subpopulations.
Thus, the only subgroup analysis that was performed included patients with the scleroderma- This group was heterogeneous and it is almost impossible to compare surv m ival rat at tes s s of f f pa pa pati ti tien en ents ts with connective tissue disease, congenital heart disease and other forms of PAH. Despite a a co omp mp mpri ri ri i si sing ng ng a al l lmos os ost t t 50 5 0 patients, this group was s s sti ti t ll l too small for r a a analy ly yzi zi zing n all subpopulations.
T Thu us us, the only y s sub ub ubgr rou oup p p an an anal al alys y ysis is t t tha ha hat t wa was pe er rf forme me med in in nc cl clud ud de ed d p pat atie ient nts s w w with th h t th he he s scl cl c e er erod od oder er rma ma af f p pec ec ectr tr trum um u o o of f f di d diso sord rd der ers s an n nd d he e er re r a a aga ga gain in in, a a a su su surv rv rviv v val al a a a adv dv van n nta a age ge ge of f f pa pa pati tien en ents ts re rece ceiv iv vin in ng g g an an ant ti tico o oag g gul ula at atio o on n was not dete ect ct tab ab able le e. . In In I f fac a a t, t, , t t the he h re re e w w was as as a a a t t tre re end nd nd to to towa wa ward rd rds s s a wo wo wors rs rse e e ou ou outc t om om ome e e of of of p p pat at a ie ie ent nt nts s s re re rece c c iving the low number of patients lost to follow-up (<3% in all subsets of patients). To the best of our knowledge, this is by far the largest series so far assessing the effects of anticoagulation in patients with PAH. Prospective enrolment of consecutive patients with newly diagnosed PAH should have minimized some potential confounders, such as immortal time bias that might favor the treatment group. On the other hand, there are considerable limitations. First, and most importantly, this was not a prospective randomized clinical trial but a prospective registry. Thus, patients receiving or not receiving anticoagulants were not randomized and therefore not entirely comparable in terms of baseline characteristics and PAH medications. As mentioned above, anticoagulants were used more frequently in patients with severe disease, which strengthens the survival signal in the anticoagulation group. However, differences in the use of targeted PAH medications must be regarded as another potential confounder. All patients in the present series were treated with PAH medications, but while treatments at baseline were comparable, combination therapies were used more frequently in the anticoagulation group during follow-up.
We cannot exclude the possibility that these differences may have affected our findings, albeit the results of the single predictor and multivariable Cox regression analyses support the notion that the observed survival advantage of patients receiving anticoagulation was independent of the PAH medications.
Second, co-morbidities were not systematically assessed in COMPERA and the presence of co-morbidities might have affected the decision to use or not to use anticoagulants as well as the survival. The reasons for withholding anticoagulation were not captured in the data base.
Third, COMPERA did not determine the quality of anticoagulation, i.e. the frequency of INR values inside and outside the target range. Fourth, bleeding complications were not systematically captured in our database. Thus, all we can state is that bleeding complications urvival signal in the anticoagulation group. However, differences in the use of t ta a arge ge g te e ed d d PA PA PAH H H medications must be regarded as another potential confounder. All patients in the present series we were re re t t tr re reat at ated ed ed w w wit th h h P PA PAH medications, but while tre re reat tm ments at basel elin i i e we we wer re re comparable, co om mb mbination th ther er rap p pie es s s w we were re re u u us se sed d mo mo more re e f f fr requ u uen ntly y in n n th he he a ant nt tic c coa oag gu gula lati ti io on g gro ro oup up p d dur ur urin in ng g fo fo f ll ll llow ow w-u u up.
We We We c can an anno not t t ex ex excl clu u ude e e th the e p po poss s ib ib ibil il lit it ity y y th th that at t the he hese se se d d dif if iffe fe ere renc nces es e m m ma ay ay h h hav av ve e af af affe fe ect cted ed o o our ur r f fin in nd di ding ng gs, a alb lbe eit t t he results of f t t the he he s s sin in ingl gl gle e e pr p ed ed edic ic icto o or r r an an and d d mu mu mult lt ltiv iv var ar aria ia abl bl b e e e Co Co C x x x re re regr gr gres es ssi si sion on on a a ana na naly ly lyse se ses s s su su upp pp ppor or ort t th the notion were responsible for approximately 2% of the deaths in our cohort and that serious bleedings occurred predominantly in the anticoagulation group, which is consistent with previous reports. 23 We have no information about less severe bleeding or the development of iron deficiency anemia in our cohorts. Fifth, despite the relatively large cohort, for some subgroups the statistical power remained low. Sixth and finally, the patients in the present series were older than patients in previous PH registries, although a similar trend has recently been reported from other European PH registries. 22 Thus, we cannot exclude the possibility that some of the patients diagnosed with IPAH may have suffered from other forms of PH such as chronic thromboembolic PH, unrecognized parenchymal lung disease or left heart disease. However, all participating centers had expertise in the management in PH and evaluated their patients according to the current guidelines. It remains to be seen if our findings are applicable to more traditional populations of predominantly younger cohorts.
In conclusion, the present data lend further support to the continued use of anticoagulation in patients with IPAH. The situation remains ambiguous for patients with other forms of PAH, for whom neither a survival benefit nor a detrimental effect can be ruled out. It is expected that the database, as it continues to grow, will provide further information on the usefulness of anticoagulation in these patient groups. In con ncl cl lu u usi io on, n, t the he he p p pre re ese se sent nt d d da at ata a le end f f fur r rthe er r s supp pp po or ort t to to t the he e c con nti i tinu nu nued ed u us se se o of f f an nti ti tico co oag ag agul ulat at atio io ion n i in in p p pat ati ien nt nts s wi wi with th h I I IPA PA PAH. H. T T The he he s sit t tu u uat ati io ion n n r re ema ma main in ins s am am ambi bi igu gu guou ou us s fo for r r pa pa pati tien en ent ts ts w w wit th h h ot ot the he er r forms of PAH AH H, , , fo fo f r r r wh wh whom om om n n nei ei eith th t er er er a a a s s sur u u vi vi viva va val l be be bene ne n fi fi f t t t no no n r a a a de de detr tr trim im men en e ta ta al l l ef ef effe fe fect ct ct c can an n b b be e e ru ru rule led out. It is s s hy hype pe ert rt rten en ensi si sion on on; PA PA PAH H, H, p p pul ul ulm mo mona ary ry ry a a art rt rter eria ial l l hy hy hype pe pert rt rten en ensi si sion on on; ; IP IP IPAH AH AH, , id id idio io opa pa path th thic ic ic p p pul ul u mo mo mona na nary ry ry a art rt ter er eria ia ial l l hypertension on n; ; PA PA PAWP WP WP, pu pu pulm m mon on onar ry y ar ar rte te t ri ri ial al a w w wed ed edge ge ge p pre re r ss s ssur ur re; e e; P P PAP AP APm m, m m mea ea ean n n pu pu pulm lm l on on o ar ar ry y y ar ar artery numbers of patients at risk at baseline and after 1, 2 and 3 years were 528, 390, 247 and 155 in the anticoagulation group and 272, 180, 127 and 65 in the no anticoagulation group. The survival difference between both groups was statistically significant (p=0.006). . Estimated survival of the other PAH cohort in accordance to anticoagu u ul la lati ti t on n n t t the he hera ra rapy py.
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